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Abstract
Background: With Fluorotype MTB (FT MTB, HAIN Lifesciences, Germany) a new semi-automated assay for detection
of M. tuberculosis complex (MTBC) in clinical specimens has been introduced. In a prospective study, we evaluated the
diagnostic performance of FT MTB in a routine diagnostic setting in a low-incidence country.
Methods: A total of 1039 respiratory specimens received for routine mycobacteriology diagnostics were analysed by
FT MTB. Results were compared to those of culture, microscopy and clinical diagnosis. 61 specimens were excluded
from further analysis due to bacterial contamination of cultures.
Results: FT MTB detected 52 of 59 TB specimens (45 culture-positive with MTBC, 7 with clinical diagnosis of TB). With
902 of 912 non-TB specimens (884 culture-negative, 18 with growth of non-tuberculous mycobacteria) FT MTB was
negative; discrepant positive FT MTB results were found with 10 specimens. Overall sensitivity, specificity, positive and
negative predictive values were 88.1%, 98.9%, 83.8% and 99.2%. Sensitivity rates for smear-positive and smear-negative
TB specimens were 100% and 56.3%, respectively. Seven of 978 samples (0.7%) yielded invalid FT MTB results.
Conclusions: FT MTB is a new accurate, half automated assay for rapidly diagnosing TB and suitable for larger series of
samples. Performance characteristics were found to be similar to those of other commercial NAATs. Its sensitivity in
paucibacillary, smear-negative specimens and its utility for TB diagnostics in high-incidence settings needs to be
addressed in further studies.
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Background
Since the introduction of rapid, easy to use nucleic acid
amplification tests (NAATs), tuberculosis (TB) diagnostics
is shifting world wide towards molecular tests. Among
commercial assays for the detection of Mycobacterium
tuberculosis complex (MTBC), Xpert MTB/RIF (Cepheid,
USA) is securing the pole position particularly in low- and
middle income countries with high burden of multi-drug
resistant TB (MDR-TB). Due to the fully integrated cart-
ridge design, the simple and safe workflow, and the ability
to simultaneously detect MTBC and rifampicin (RMP)
resistance, Xpert MTB/RIF allows rapid TB diagnosis and
drug resistance testing also at the peripheral health clinic
level [1,2]. In fully industrialized countries however, these
strengths do not prove similarly effective. First, TB inci-
dence as well as RMP resistance rate is comparably low.
In Germany, for example, TB incidence is still declining
reaching 5.3% in 2011; MDR-TB rate is at around 2% [3].
Second, the price per shot is high compared to other
commercial assays. Finally, TB NAATs are often processed
in large batches in which Xpert MTB/RIF would not offer
significant time savings. Therefore, semi-automated assays
designed for larger series are more attractive for many
mycobacteriology laboratories in low-prevalence settings.
Widely used semi-automated assays are, for example,
COBAS TaqMan MTB (CTM-MTB) (Roche, Germany),
BD probeTEC ET (probeTEC, Becton-Dickenson, USA)
or Gen-Probe Amplified MTB Direct Test (AMDT,
Gene-Probe, USA). Most of them are able to detect
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MTBC with specificities of nearly 100% whereas sensi-
tivities appear more variable, in particular with pauci-
bacillar specimens [4-7]. In direct comparison studies,
performance characteristics have been shown to be in
the range of that of Xpert MTB/RIF [8-10]. While pro-
beTEC and AMDT are demanding many open work
steps with certain risk of cross-contamination, CTM-MTB
is, so far, the only one considered to be semi-automated
using a real-time PCR platform [5].
Most recently, a new semi-automated assay has been
introduced for rapid detection of MTB complex from
respiratory and non-respiratory clinical specimens.
The FluoroType MTB (FT MTB, HAIN Lifescience,
Germany) is a HyBeacon-based PCR assay performed
on a Fluorocycler instrument allowing amplification
and detection in a closed system. The aim of our present
study was to comprehensively evaluate FT MTB for the
routine detection of MTBC in respiratory specimens
and to compare the results to conventional culture,
microscopy and clinical data.
Methods
Clinical specimens
In total, 1039 respiratory specimens (390 sputa, 556 bron-
chial aspirates, 89 bronchoalveaolare lavages, 4 tracheal
secretes) were included in the study. They originated from
patients with suspected infection by MTBC or non-
tuberculous mycobacteria (NTM) and were sent for rou-
tine mycobacteriology diagnostics between March and
July 2012. The study protocol, involving the use of clinical
specimens and human data, has been approved by the
ethics committees of the Bayrische Landesärztekammer
(no. 06043) and the Ludwig-Maximilian University of
Munich (no. 437-12). In the scope of an open prospective
study, consecutive specimens were taken provided that
(i) sputum material was of sufficient quality, (ii) enough
material was available to perform Fluorotype MTB assay
in addition to requested routine analyses, (iii) material
from the same patient has not been tested more than one
time before and (iv) the material did not come from a
known TB patient under therapy or with a known history
of TB, provided this information was available at the time
of enrolment.
All specimens were decontaminated using N-acetyl-L-
cysteine (NALC)-NaOH. After concentration by centri-
fugation, the sediment was resuspended in 1.5 ml of
0.5 M phosphate buffer (pH 6.8) and inoculated in li-
quid (MGIT™, Becton-Dickinson, Heidelberg, Germany),
Loewenstein-Jensen and Stonebrinck medium. Smears
were prepared from this suspension, stained with Auramin
O and visualized with a fluorescence microscope (mag-
nification × 400). From the leftover suspension DNA
was prepared and used directly for Fluorotype MTB
assay or stored frozen.
Cultures were incubated for up to 8 weeks. In case a pri-
mary culture turned positive with acid fast bacilli, the isolate
was identified by DNA line probe assays (Genotype CM,
Genotype MTBC, Hain Lifesciences, Nehren, Germany) or
by sequencing of the 16S rRNA gene.
DNA preparation
Fully automated isolation of DNA was done using the
GenoXtract automat (HAIN Lifesciences) and the GTX
DNA/RNA Extraction Kit, according to the instructions
of the manufacturer. In brief, 700 μl decontaminated
material was transferred into a screw cap container and
heat inactivated at 100°C for 20 min. Subsequently,
pump-pipette-tip units, reagent cartridges, and elution
containers were mounted in the GenoXtract machine. The
protocol was started. After about 40 min the ready-to-use
DNA was isolated in a volume of 100 μl elution buffer.
Fluorotype MTB assay
Fluorotype MTB test is performed on a FluoroCycler
(HAIN Lifesciences) and combines DNA amplification
using specific primers and subsequent melting curve
analysis in one instrument. First, PCR mixes were freshly
prepared by combining 3 μl amplification mix A (AM-A)
with 7 μl amplification mix B (AM-B) in the pre-
amplification room I. Subsequently, 6 μl of isolated
DNA was added in the pre-amplification room II. Con-
trols included 6 μl of PCR-grade water (negative con-
trol) and 6 μl of control DNA C + FT MTB (positive
control). PCR mixes were immediately loaded into the
FluoroCycler. Results were available after 2 hours 10 min.
The FluoroSoftware automatically analyzed melting curves
for the amplification control (AC) (70.5°C +/- 3°C) and for
MTBC (melting point 60.0°C +/- 3°C) and computed
results as “no MTB complex DNA detected” (MTBC
negative, AC positive), “MTB complex DNA detected”
(MTBC positive, AC positive or negative), “not interpret-
able” in case of unspecific peaks, or “invalid” in case of
failure of positive/negative controls or AC.
Analysis of results
FT MTB results were initially compared to outcomes of
the cultures. In cases of discrepant results, clinical,
histological and anamnesis data of the patients were in-
cluded in the final evaluation. For example, an initially
discrepant positive FT MTB result (FT MTB positive,
culture negative) was re-classified “true positive” if the
patient was finally diagnosed as TB case by other means,
i.e. by combinations of medical history, clinical examin-
ation, radiology, histopathology, and treatment success
with anti-TB regimens. Invalid or not interpretable
results were excluded from the final calculation of sensi-
tivity, specificity and prospective values. Calculations of
positive and negative predictive values were based on
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the detected prevalence of 6% (59/971), which is largely
in agreement with prevalence values found in laboratories
of many low-prevalence countries. 95% confidence inter-
vals were determined using the Vassar-Stats calculator.
Statistical analyses were performed using unpaired t tests
on the OpenEpi version 2.3 platform. A P value of <0.05
was considered statistically significant.
Results
Comparison of FT MTB with culture data
In total, 1039 respiratory specimens were analysed by
FT MTB and, in parallel, subjected to microscopy and
culture. 908 of 1039 specimens (87.4%) were culture-
negative, 18 (1.7%) yielded growth of NTMs (9M. intra-
cellulare, 4M. gordonae, 2M. avium, 2M. fortuitum, 1
M. abscessus), and 52 (5.0%) growth of MTBC (51 MTB,
1M. caprae) (Table 1). Of the latter ones, 42 specimens
(86.7%) were smear-positive. Bacterial contamination of
liquid or solid cultures was observed in 61 of 1039
(5.8%) cases. They were excluded from further analysis.
Of the remaining 978 specimens, FT MTB results were
negative in 909 (92.9%) and positive in 62 (6.3%) cases
(Table 1). Seven (0.7%) specimens yielded invalid FT MTB
results. 902 of 909 (99.2%) negative FT MTB results
matched with culture: 884 specimens yielded negative
culture and from 18 specimens NTM grew (Table 1). Dis-
crepant results were found with seven FT MTB negative
specimens, which were all smear-negative but MTB grew
in liquid culture; they were considered false-negative. 45
of 62 (72.6%) FT MTB positive specimens were in agree-
ment with culture results: they grew MTBC in culture and
93.3% of them (42/45) were smear-positive. 17 of 62
(27.4%) FT MTB positive specimens were culture-negative
and thus considered “discrepantly positive”. All but one of
them (94.1%) showed a smear negative microscopy.
Analysis of discrepant results
All 17 discrepantly positive FT MTB derived from pa-
tients without positive culture from any materials sent
to our laboratory, i.e. none of the patients were
registered in our records as a TB case. Nonetheless,
seven cases were diagnosed with TB after review of the
patients’ charts. Consequently, we re-classified the re-
sults from 7 of 17 specimens as “true-positive”. Two of
them were recovered from patients with clinically and
histological confirmed tuberculosis although cultures con-
sistently remained negative. Further two specimens were
recovered from patients already receiving TB therapy at
the time of specimen collection; one of them was smear-
positive. The patients’ records indicated that other myco-
bacteriology laboratories reported positive cultures from
previous specimens. Three specimens were obtained from
patients with a recent history of TB. All three had already
successfully completed TB therapy within the previous
10 months and requested now diagnostic work-up for the
suspicion of relapse. The remaining 10 specimens with
discrepantly positive FT MTB originated from patients
without any documented history or diagnosis of TB and
were finally classified false-positive (Table 2).
Although FT MTB is a qualitative assay, signal values of
melting curve peaks can be read from the corresponding
graphs. Notably, false-positive results (n = 10) showed
significantly lower MTBC-specific peak values (mean
257 units; standard deviation [SD] ±121.6 units) com-
pared to that of true-positive results (mean 650 units;
SD ±87.5) (p < 0.001) (Figure 1). All but one of false-
positive results showed values below 320 suggesting the
existence of a critical zone of “low grade positivity”.
Sensitivity and specificity
After resolving discrepant and excluding invalid values, 10
out of 912 “no TB” specimens yielded positive FT MTB
results corresponding to a specificity of 98.9% (Table 2).
52 out of 59 “TB” specimens yielded positive FT MTB
results corresponding to an overall sensitivity of 88.1%.
With smear-negative specimens, sensitivity was 56.3%
(9/16), with smear positive ones 100% (43/43) (Table 2).
Based on a prevalence of 6% TB specimens among the
971 study samples, positive and negative predictive
values were calculated to 83.8% and 99.2%, respectively.
Discussion
The FT MTB assay is a new semi-automated assay for
detection of MTBC giving results within 3-4 hours.
Similar to other semi-automated systems like COBAS
TaqMan MTB, different workstations are required in-
cluding DNA extraction, preparation of PCR mixes and
amplification/detection. DNA extraction can be done
automated using the GenoXtract instrument requiring
only minimal hands-on time. Furthermore, amplifica-
tion and detection is performed fully-automated in the
Fluorocycler instrument; the handling of the instru-
ment is simple and the analysis software designed user-
friendly. Including all work steps, hands-on time for 12
Table 1 Comparison of FT MTB and culture results
No. of specimens with FT MTB results
Culture resultsa Pos Neg Invalid Total
MTBC 45 7 0 52
Smear positive 42 0 0 42
Smear negative 3 7 0 10
No MTBC 17 902 7 926
Culture negative 17 884 7 908
Growth of NTM 0 18 0 18
Total 62 909 7 978
aMTBC, Mycobacterium tuberculosis complex; NTM, non-tuberculous mycobacteria;
pos, positive; neg, negative.
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specimens adds up to approximately 30 min being
comparable to other semi-automated systems [10]. The
Fluorocycler system is suitable for low numbers of sam-
ples as well as for large series, as up to 8 Fluorocycler
instruments (each with 12 positions) can be operated
simultaneously by one control computer. In compari-
son, the Xpert MTB/RIF system enables hands-on time
of less than 3 min per specimens being of advantage
only when handling a small number of samples.
The aim of the present study was to assess the perform-
ance characteristics of the FT MTB assay in a routine
setting of a German mycobacteriology laboratory. FT MTB
results from 978 respiratory specimens were compared
to culture and clinical diagnosis as “gold standard”. The
specificity (98.9%) of FT MTB was in the range of that
of other NAATs (98.4%-99.7%, mean 99.1%) [2,4-6,11,12].
In particular, no cross-reactivity with 18 specimens grow-
ing NTM was observed. Ten positive FT MTB results
remained unresolved, even after review of patients` clin-
ical data. It remains elusive whether these false-positive
outcomes are caused by residual MTBC DNA despite
absence of active disease, as speculated before [13], or by
unspecific amplification. Although reported as positive by
the manufacturers’ analysis software, false-positive FT
MTB tests seem to give lower MTBC-specific melting
curve peaks than true-positive ones. Discrepant positive
results in the “zone of low-positivity” are reported also for
other NAAT systems [14-16]. A repeat testing is, there-
fore, generally recommended for specimens with low posi-
tivity values before transferring a final laboratory report to
the clinical doctor.
The overall sensitivity of FT MTB reached 88.1% being
in the upper range (63.2 – 95.0%, mean 84.2%) of levels
reported for other commercial NAATs like BD ProbeTec
ET (63.2-86.2%) [6,11], COBAS Taqman MTB (81.1-91.5%)
[4,5], GeneProbe AMTD (95%) [12], Speed-oligo direct
MTB (76%) [17] or Xpert MTB/RIF (88.0-92.2%) [2,18].
Considering smear-positive TB specimens only, sensi-
tivity and PPV reached 100%. In comparison, sensitivity
levels reported for other commercial assays were 95.5%
to 100% [2,5,6,17-19]. A high positive predictive value
for smear-positive specimens is particularly important in
settings where NTM are common. Particularly in fully
industrialized countries, NTM are increasingly isolated
from clinical specimens and reported as cause of oppor-
tunistic infections mainly in immunocompromised indi-
viduals [20-22]. Therefore, modern NAAT assays should
rapidly and reliably differentiate between TB and NTM
infection, particularly in patients with immunodeficiency
or in patients with first smear-positive sputa and unspe-
cific clinical signs of TB. The FT MTB obviously fulfils
this requirement.
Considering smear-negative TB specimens only, the
sensitivity of FT MTB was 56.3%. Of the smear-negative
TB samples which were missed by FT MTB, four
Table 2 Resolved results for sensitivity, specificity, PPV and NPV of FT MTB (culture and clinical diagnosis)
No. of specimens with indicated results by
culture and clinical data (n = 971)a
TB (n = 59) no TB (n = 912)
FT MTB pos FT MTB neg FT MTB pos FT MTB neg Sensitivity Specificity PPV NPV
Smear microscopy (%) (%) (%) (%) (95% CI) (95% CI) (95% CI) (95% CI)
Smear positive 43 0 0 3 100 100 100 100
(82.7) (0) (0) (0.3) (89.7-100) (30.9-100) (89.7-100) (30.9-100)
Smear negative 9 7 10 899 56.3 98.9 47.3 99.2
(17.3) (100) (100) (99.7) (30.5-79.2) (97.9-99.4) (25.2-70.5) (98.3-99.6)
All 52 7 10 902 88.1 98.9 83.8 99.2
(76.4-94.6) (97.9-99.4) (72.8-91.5) (98.3-99.6)















False-positive (n=10) True-positive (n=52)
Figure 1 Comparison of false-positive and true-positive results.
MTBC-specific melting curve peak values for false-positive (left, n = 10)
and true-positive (right, n = 52) FT MTB results are shown. Boxes in
grey (false-positive) and white (true-positive) represent means of
values ± standard deviation, respectively. Maximum and minimum
values are depicted by vertical lines. Dotted lines show median values.
Hofmann-Thiel and Hoffmann BMC Infectious Diseases 2014, 14:59 Page 4 of 5
http://www.biomedcentral.com/1471-2334/14/59
exhibited positive culture results only after ≥ 24 days
of incubation, indicating a paucibacillary nature of the
specimens. This doesn’t mitigate the fact, that we found
a sensitivity level for smear-negative samples which was
in the lower range of values reported for other NAATs
(49.1–86.7%, mean 64.1%) [2,4,6,12,17,18]. However, the
low absolute number of smear-negative TB samples
(n = 16) included in the present study might have biased
the outcomes for such samples. Consequently, the sensi-
tivity of FT MTB for paucibacillary specimens should be
re-assessed in further, preferably multi-centre studies with
higher numbers of smear-negative TB samples.
Conclusions
In summary, FT MTB has proven to be a fast, easy and
accurate new assay for direct detection of MTBC. The
assay yielded good performance characteristic in terms
of overall sensitivity and specificity with a potential weak-
ness regarding sensitivity in smear-negative specimens
which needs to be addressed in further investigations. Due
to its user-friendly design, the closed system for amplifica-
tion and detection and the possibility of simultaneously
processing up to 96 samples without significant loss of
time, FT MTB is an alternative to other semi- or fully
automated assays particularly in low-prevalence countries.
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